顺阿曲库铵与维库溴铵在急性呼吸窘迫综合征患者或有风险患者中的疗效观察性研究
该观察性研究利用全国代表性数据库,纳入ICU内诊断ARDS或有ARDS风险因素、接受机械通气、且在入院2天内开始持续输注神经肌肉阻滞剂至少2天的患者,倾向性匹配后比较顺阿曲库铵组与维库溴铵组各1901例。结果显示两组住院死亡率无显著差异(OR 0.932,P=0.40),住院天数无显著差异(-0.66天,P=0.411);顺阿曲库铵组机械通气天数更少(-1.01天,P=0.005)、ICU天数更少(-0.98天,P=0.028),出院回家可能性无显著差异(OR 1.19,P=0.056)。作者认为顺阿曲库铵可能是ARDS或有ARDS风险患者的首选神经肌肉阻滞剂。
要点
- 在ARDS或有ARDS风险、持续输注神经肌肉阻滞剂≥2天的机械通气患者中,顺阿曲库铵与维库溴铵的住院死亡率无显著差异(OR 0.932,P=0.40)。
- 顺阿曲库铵组较维库溴铵组机械通气天数减少1.01天(P=0.005),ICU天数减少0.98天(P=0.028)。
- 两组住院天数无显著差异(-0.66天,P=0.411),出院回家可能性无显著差异(OR 1.19,P=0.056)。
- 作者认为,对于ARDS或有ARDS风险的患者,顺阿曲库铵可能是首选的神经肌肉阻滞剂。
适用人群与场景
- ICU内诊断ARDS或有ARDS风险因素、接受机械通气、且在入院2天内开始持续输注神经肌肉阻滞剂至少2天的患者。
研究设计与关键结果
- 研究类型为观察性研究,使用全国代表性数据库,经倾向性匹配纳入3802例患者(顺阿曲库铵组1901例,维库溴铵组1901例)。
- 主要结局住院死亡率:顺阿曲库铵组与维库溴铵组无显著差异(OR 0.932,P=0.40)。
- 机械通气天数:顺阿曲库铵组较维库溴铵组减少1.01天(P=0.005)。
- ICU天数:顺阿曲库铵组较维库溴铵组减少0.98天(P=0.028)。
- 住院天数:两组无显著差异(-0.66天,P=0.411)。
- 出院回家可能性:两组无显著差异(OR 1.19,P=0.056)。
证据类型、等级与局限
- 证据类型:观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于ARDS或有ARDS风险的患者,顺阿曲库铵可能是首选的神经肌肉阻滞剂。
- 研究显示顺阿曲库铵与维库溴铵相比不改善住院死亡率,但可能减少机械通气天数和ICU天数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: The neuromuscular blocking agent cisatracurium may improve mortality for patients with moderate-to-severe acute respiratory distress syndrome (ARDS). Other neuromuscular blocking agents, such as vecuronium, are commonly used and have different mechanisms of action, side effects, cost, and availability in the setting of drug shortages.
OBJECTIVES: To determine whether cisatracurium is associated with improved outcomes when compared with vecuronium in patients at risk for and with ARDS.
METHODS: Using a nationally representative database, patients who were admitted to the ICU with a diagnosis of ARDS or an ARDS risk factor, received mechanical ventilation, and were treated with a continuous infusion of neuromuscular blocking agent for at least 2 days within 2 days of hospital admission were included. Patients were stratified into two groups: those who received cisatracurium or vecuronium. Propensity matching was used to balance both patient- and hospital-specific factors. Outcomes included hospital mortality, duration of mechanical ventilation, ICU and hospital duration, and discharge location.
MEASUREMENTS AND MAIN RESULTS: Propensity matching successfully balanced all covariates for 3,802 patients (1,901 per group). There was no significant difference in mortality (odds ratio, 0.932; P = 0.40) or hospital days (-0.66 d; P = 0.411) between groups. However, patients treated with cisatracurium had fewer ventilator days (-1.01 d; P = 0.005) and ICU days (-0.98 d; P = 0.028) but were equally likely to be discharged home (odds ratio, 1.19; P = 0.056).
CONCLUSIONS: When compared with vecuronium, cisatracurium was not associated with a difference in mortality but was associated with improvements in other clinically important outcomes. These data suggest that cisatracurium may be the preferred neuromuscular blocking agent for patients at risk for and with ARDS.
参考来源
- Sottile PD, Kiser TH, Burnham EL, et al. An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018. PMID: 29241014. doi:10.1164/rccm.201706-1132OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。